Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago phase 2 consortium Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Interleukin-6
  • Prostatic Neoplasms

abstract

  • Vorinostat at this dose was associated with significant toxicities limiting efficacy assessment in this patient population. The significant association between IL-6 levels and removal from the study for toxicities warrants further investigation.

publication date

  • January 12, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2917101

Digital Object Identifier (DOI)

  • 10.1002/cncr.24597

PubMed ID

  • 19711464

Additional Document Info

start page

  • 5541

end page

  • 9

volume

  • 115

number

  • 23